Automation Is Here To Stay … Hip Hip Hooray!
“Success is the ability to go from one failure to another with no loss of enthusiasm.” So said Winston Churchill, who noted that persistence was not a universal quality amongst his peers. “Never give up.”The problem is, humans are ill-prepared to approach a situation for the hundredth or millionth time without at least facing some dip in performance. The answer is automation, a growing trend in digital investments and one which has recently entered the pharmaceutical industry. Computers can try and try again, with just as much fervor as with the first attempt.Despite this obvious advantage, when we think of automa...
Source: EyeForPharma - February 26, 2019 Category: Pharmaceuticals Authors: Catherine Calarco Source Type: news
Automation Is Here To Stay … Hip Hip Hooray!
“Success is the ability to go from one failure to another with no loss of enthusiasm.” So said Winston Churchill, who noted that persistence was not a universal quality amongst his peers. “Never give up.”The problem is, humans are ill-prepared to approach a situation for the hundredth or millionth time without at least facing some dip in performance. The answer is automation, a growing trend in digital investments and one which has recently entered the pharmaceutical industry. Computers can try and try again, with just as much fervor as with the first attempt.Despite this obvious advantage, when we think of automa...
Source: EyeForPharma - February 26, 2019 Category: Pharmaceuticals Authors: Catherine Calarco Source Type: news
The future of patient services
Channels: Access and EvidenceMedicalMultichannelPatients and MedicalImage: URL: http://bit.ly/2BuzY1BExclude from Homepage: No (Source: EyeForPharma)
Source: EyeForPharma - February 11, 2019 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
RWE: The Missing Link
This article is from our latest ' Trends in Real-World Evidence ' magazine. Download for free.Data linkage challenges
Linking data is not an easy process; not only does it require the right technological tools and knowhow, it raises a range of concerns, from patient anonymity and data ownership, to how to transcend geographical barriers.Anonymizing data is a fundamental challenge, says Nigel Hughes, Scientific Director at Janssen Clinical Innovation – Patient Data for Research. “Data linkage requires, via an underlying consent model, linking different data together – with the patient being the common linker.”He ...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
RWE: The Missing Link
This article is from our latest ' Trends in Real-World Evidence ' magazine. Download for free.Data linkage challenges
Linking data is not an easy process; not only does it require the right technological tools and knowhow, it raises a range of concerns, from patient anonymity and data ownership, to how to transcend geographical barriers.Anonymizing data is a fundamental challenge, says Nigel Hughes, Scientific Director at Janssen Clinical Innovation – Patient Data for Research. “Data linkage requires, via an underlying consent model, linking different data together – with the patient being the common linker.”He ...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
What Can Pharma Expect in 2019?
For those of us that use the Gregorian calendar, this time of year is one for reflection. We look back at the year just gone and forward to the year to come and, armed with a list of best-self resolutions, we step into January full of hope and intention.Like most years, 2018 was a busy one for the pharmaceutical industry – best characterized perhaps not as a year of radical change but as 12 months of under-the-surface action. (But if you disagree,please do let me know).To this editorial team it appears that companies are starting to get to grips with some of the big trends that have swept the industry over the past few y...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: The eyeforpharma Editorial Team Source Type: news
What Can Pharma Expect in 2019?
For those of us that use the Gregorian calendar, this time of year is one for reflection. We look back at the year just gone and forward to the year to come and, armed with a list of best-self resolutions, we step into January full of hope and intention.Like most years, 2018 was a busy one for the pharmaceutical industry – best characterized perhaps not as a year of radical change but as 12 months of under-the-surface action. (But if you disagree,please do let me know).To this editorial team it appears that companies are starting to get to grips with some of the big trends that have swept the industry over the past few y...
Source: EyeForPharma - January 7, 2019 Category: Pharmaceuticals Authors: The eyeforpharma Editorial Team Source Type: news
Gold Standard: Standardizing RWD
This article is from our latest ' Trends in Real-World Evidence ' magazine. Download for free.A Herculean task?The banking industry – often compared to healthcare due to similar levels of regulation – may offer some insight, says Hassan Chaudhury, Director and Co-founder at Health iQ.“Citibank manages untold billions and makes sure that credit flows through from, say, New York to London. They need to track credit, use different systems and have regulators using different systems, as well as talk to different lenders. They all work with each other in microseconds and on differe nt platforms.”If banks can do it, wh...
Source: EyeForPharma - January 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
Gold standard: Standardizing RWD
Within healthcare circles, the hype around the potential of real-world evidence to transform health outcomes through new patient insights has been considerable.But as the pool of RWD swells daily – driven by growing demand from drug development, regulatory decision-making and patient care and enhanced by advances in technology, study design and data collection methods – there is one very large stumbling block on the horizon.“As data is collected in multiple languages, formats, ontologies, structures, and platforms, you end up with a Tower of Babel challenge,” says Nigel Hughes, Scientific Director, Janssen Clinical...
Source: EyeForPharma - January 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news
